banner

News Releases

None | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
Date Title
11/10/20
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
11/04/20
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
10/26/20
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
10/21/20
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
10/14/20
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
10/06/20
Michael J. Fox Foundation and Acadia Pharmaceuticals Partner to Share Resources and Foster Dialogue on Cognitive Changes and Other Non-Motor Symptoms in Parkinson’s Disease
10/01/20
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
09/02/20
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
08/31/20
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
08/25/20
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
08/12/20
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
08/05/20
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
07/29/20
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
07/22/20
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
07/20/20
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
07/20/20
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
06/15/20
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
06/02/20
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
05/28/20
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
05/26/20
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
05/21/20
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
05/07/20
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
05/07/20
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
05/05/20
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
04/15/20
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
03/03/20
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
02/26/20
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
02/24/20
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
02/12/20
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
01/07/20
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020